JP2005516997A - 心筋損傷の阻止のためのインスリン様増殖因子iスプライス変異体の使用 - Google Patents

心筋損傷の阻止のためのインスリン様増殖因子iスプライス変異体の使用 Download PDF

Info

Publication number
JP2005516997A
JP2005516997A JP2003565505A JP2003565505A JP2005516997A JP 2005516997 A JP2005516997 A JP 2005516997A JP 2003565505 A JP2003565505 A JP 2003565505A JP 2003565505 A JP2003565505 A JP 2003565505A JP 2005516997 A JP2005516997 A JP 2005516997A
Authority
JP
Japan
Prior art keywords
mgf
polypeptide
sequence
igf
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003565505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516997A5 (cg-RX-API-DMAC7.html
Inventor
ゴールドスピンク,ジョフリー
ゴールドスピンク,ポール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Publication of JP2005516997A publication Critical patent/JP2005516997A/ja
Publication of JP2005516997A5 publication Critical patent/JP2005516997A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2003565505A 2002-02-07 2003-02-06 心筋損傷の阻止のためのインスリン様増殖因子iスプライス変異体の使用 Pending JP2005516997A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202906.4A GB0202906D0 (en) 2002-02-07 2002-02-07 Prevention of myocardial damage
PCT/GB2003/000537 WO2003066082A1 (en) 2002-02-07 2003-02-06 Use of the insulin-like-growth factor i splice variant mgf for the prevention of myocardial damage

Publications (2)

Publication Number Publication Date
JP2005516997A true JP2005516997A (ja) 2005-06-09
JP2005516997A5 JP2005516997A5 (cg-RX-API-DMAC7.html) 2006-10-19

Family

ID=9930632

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003565505A Pending JP2005516997A (ja) 2002-02-07 2003-02-06 心筋損傷の阻止のためのインスリン様増殖因子iスプライス変異体の使用

Country Status (9)

Country Link
US (4) US20050048028A1 (cg-RX-API-DMAC7.html)
EP (1) EP1480669B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005516997A (cg-RX-API-DMAC7.html)
AU (1) AU2003244511A1 (cg-RX-API-DMAC7.html)
DK (1) DK1480669T3 (cg-RX-API-DMAC7.html)
ES (1) ES2432082T3 (cg-RX-API-DMAC7.html)
GB (1) GB0202906D0 (cg-RX-API-DMAC7.html)
PT (1) PT1480669E (cg-RX-API-DMAC7.html)
WO (1) WO2003066082A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
WO2006097682A1 (en) * 2005-03-18 2006-09-21 Ucl Business Plc Mechano growth factor peptides and their use
CA2601227A1 (en) * 2005-03-18 2006-09-21 Ucl Business Plc Mecano growth factor peptides and their use
CL2007001614A1 (es) 2006-06-09 2008-08-08 Novartis Ag Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t
WO2009012443A1 (en) * 2007-07-18 2009-01-22 The Board Of Trustees Of The University Of Illinois Nanoparticles for the elution of growth factors for recovery and regeneration of organs
CN101891812B (zh) * 2010-07-09 2012-10-17 山西大学 力生长因子多肽及其制备方法和用途
CN103031277B (zh) * 2011-09-29 2015-07-15 重庆大学 力生长因子在制备无血清培养耐受型哺乳动物工程细胞中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460147C2 (de) 1974-12-19 1983-05-05 Ibm Deutschland Gmbh, 7000 Stuttgart Anordnung zur Dekomprimierung komprimierter Information für aus schwarzen und weißen Bereichen zusammengesetze darzustellende Zeichen
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4963665A (en) 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
DK0437563T3 (da) 1989-08-07 1995-05-29 Debio Rech Pharma Sa Bioligiske aktive lægemiddelpolymerderivater
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
SE9101341D0 (sv) 1991-05-03 1991-05-03 Kabi Pharmacia Ab New medicinal use
ES2101865T3 (es) * 1991-08-01 1997-07-16 Genentech Inc Igf-1 para mejorar el estado neural.
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
CA2123685C (en) 1991-11-25 2003-10-07 Hans-Arne Hansson Medicament for promoting growth of mammalian nerve
FR2687681B1 (fr) * 1992-02-20 1995-10-13 Transgene Sa Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
WO1995013290A1 (en) 1993-11-12 1995-05-18 North Shore University Hospital Research Corporation Method of treating muscular dystrophy
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5650496A (en) * 1995-04-14 1997-07-22 Cephalon, Inc. IGF-I purification process
GB9605124D0 (en) * 1996-03-11 1996-05-08 Royal Free Hosp School Med Method of treating muscular disorders
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
PT1075282E (pt) 1998-04-28 2005-09-30 Applied Research Systems Conjugados analogos de peg-lhrh
GB9926968D0 (en) 1999-11-15 2000-01-12 Univ London Treatment of neurological disorders
GB0011278D0 (en) * 2000-05-10 2000-06-28 Univ London Repair of nerve damage
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
GB0203552D0 (en) 2002-02-14 2002-04-03 Beaumont Nicholas J Peptide growth factor
WO2006097682A1 (en) 2005-03-18 2006-09-21 Ucl Business Plc Mechano growth factor peptides and their use

Also Published As

Publication number Publication date
US9919031B2 (en) 2018-03-20
DK1480669T3 (da) 2013-05-06
US20130210723A1 (en) 2013-08-15
EP1480669A1 (en) 2004-12-01
US20080039390A1 (en) 2008-02-14
AU2003244511A1 (en) 2003-09-02
EP1480669B1 (en) 2013-01-23
PT1480669E (pt) 2013-05-22
WO2003066082A1 (en) 2003-08-14
US20180271942A1 (en) 2018-09-27
GB0202906D0 (en) 2002-03-27
US20050048028A1 (en) 2005-03-03
ES2432082T3 (es) 2013-11-29

Similar Documents

Publication Publication Date Title
US20180271942A1 (en) Use of the Insulin-Like-Growth Factor 1 Splice Variant MGF for the Prevention of Myocardial Damage
JP4131569B2 (ja) インシュリン様成長因子i(igf−i)発現系及び使用法
US20250001014A1 (en) Bag3 compositions and methods
US20130123340A1 (en) Compositions and methods for the treatment and prevention of cardiac ischemic injury
US10907153B2 (en) Treatment of heart disease by inhibtion of the action of muscle A-kinase anchoring protein (mAKAP)
US20250320509A1 (en) Compositions and methods for treating wilson's disease
US7345158B2 (en) Actin related cytoskeletal protein “LACS”
JP2003520784A (ja) 神経障害を治療するためのインスリン様増殖因子iイソ型mgfの使用
EP3227441B1 (en) Camkk1 as a novel regenerative therapeutic
EP1967210A1 (en) Novel application of apelin
JPH11146790A (ja) Dtdst遺伝子発現ベクター
WO2025240625A1 (en) Cbin1 therapy improves atrial electrical and functional remodeling, limiting atrial arrhythmias in failing hearts
JP2024538849A (ja) 哺乳動物の心臓再生
US7309606B2 (en) Methods and compositions for treating hypercholesterolemia
WO2024249772A2 (en) Cpt1 gene therapy and methods for treating or preventing cardiovascular diseases
JP2025524525A (ja) Hippoシグナル伝達の遺伝子治療は、臨床的に適切なモデルにおける心臓機能を改善する
CN115957301A (zh) 一种促进心梗心肌修复的细胞分泌因子及应用
Baranov et al. The current state and prospects of the gene therapy of duchenne muscular dystrophy worldwide and in Russia
JP2016131541A (ja) トランスジェニック非ヒト哺乳動物及びその用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090715

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091021

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091201